Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.67 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HRH2 | P25021 | 1/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6719074 | 0.99 | TLR7 (0.66) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL10589524 | 0.89 | TLR7 (0.84) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL5122832 | 0.89 | TLR7 (0.69) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL3872728 | 0.89 | TLR7 (0.71) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL1490612 | 0.88 | TLR7 (0.71) | TLR7TLR8LMNAPOLBHRH2 | |
| Hydrochloric Acid SCHEMBL5451745 | 0.88 | TLR7 (0.67) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL1301722 | 0.86 | TLR7 (0.72) | TLR7TLR8 | |
| Hydrochloric Acid SCHEMBL9602146 | 0.86 | TLR7 (0.80) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL13533456 | 0.85 | TLR7 (0.65) | TLR7TLR8 | |
| SCHEMBL1490402 | 0.85 | TLR7 (0.65) | TLR7TLR8LMNAPOLBHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0582581-B1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING & MFG (US) | 1999-05-06 | — | — | EP | claimed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8598192-B2 | Hydroxylamine substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-12-03 | — | — | US | disclosed |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2006086634-A2 | OXIME AND HYDROXYLAMINE SUBSTITUTED IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| EP-1685129-A2 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1682544-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006009832-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005123079-A2 | UREA SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005048945-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005048933-A2 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20020115861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-22 | — | — | US | disclosed |
| US-6348462-B1 | VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2002-02-19 | — | — | US | disclosed |
| US-5977366-A | 1-substituted, 2-substituted 1H-imidazo[4,5-c] quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | TLR7 1484/4885TLR8 2396/4885LMNA 2918/4885 |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | TLR7 1484/4885TLR8 2396/4885LMNA 2918/4885 |
| US-20020115861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines | IFNAR1, IFNG, IRF3 | TLR7 54/4885TLR8 335/4885LMNA 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.